Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study

Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study

Bibliographic Details
Main Authors:	Ivan Barenboim, Beny Lafer
Format:	Article
Language:	English
Published:	Associação Brasileira de Psiquiatria (ABP)
Series:	Brazilian Journal of Psychiatry
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462018000100110&lng=en&tlng=en

Similar Items

Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study
by: Paul Glue, et al.
Published: (2020-05-01)

Transient effects of multi‐infusion ketamine augmentation on treatment‐resistant depressive symptoms in patients with treatment‐resistant bipolar depression – An open‐label three‐week pilot study
by: Chuanjun Zhuo, et al.
Published: (2020-08-01)

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
by: Wilkowska A, et al.
Published: (2021-08-01)

Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
by: Adem T. Can, et al.
Published: (2021-02-01)

Magnesium in Ketamine Administration in Treatment-Resistant Depression
by: Natalia Górska, et al.
Published: (2021-05-01)

Adjunct ketamine treatment of depression in treatment‐resistant schizophrenia patients is unsatisfactory in pilot and secondary follow‐up studies
by: Chuanjun Zhuo, et al.
Published: (2020-05-01)

Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression
by: Jakub Słupski, et al.
Published: (2020-12-01)

Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression
by: Joanna Szarmach, et al.
Published: (2021-03-01)

Open label trial of rTMS for treatment resistant depression in youth
by: Q. McLellan, et al.
Published: (2017-03-01)

Tratamento da depressão bipolar The treatment of bipolar depression
by: Beny Lafer, et al.
Published: (2005-01-01)

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
by: Szarmach J, et al.
Published: (2020-10-01)

Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine
by: Linda Xing Yu Liu, et al.
Published: (2021-06-01)

Ketamine for treatment-resistant depression : Moving away from conventional antidepressants
by: Blom, Emma-Clara
Published: (2021)

An Open Label Trial of Clustered Maintenance rTMS for Patients with Refractory Depression
by: Paul B. Fitzgerald, et al.
Published: (2013-05-01)

Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
by: Erik D. Fagerholm, et al.
Published: (2021-05-01)

A qualitative study of patients' experience of ketamine treatment for depression: The ‘Ketamine and me’ project
by: Chris Griffiths, et al.
Published: (2021-04-01)

Amisulpride as adjunct to clozapine in treatment-resistant schizophrenia and schizoaffective disoder: An open-label pilot study
by: Liezl Koen, et al.
Published: (2006-03-01)

Neural and Behavioral Correlates of Clinical Improvement to Ketamine in Adolescents With Treatment Resistant Depression
by: Michelle Thai, et al.
Published: (2020-08-01)

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
by: Carola Rong, et al.
Published: (2018-04-01)

Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine
by: Yanling Zhou, et al.
Published: (2021-09-01)

Duloxetine in the treatment of major depressive disorder: an open-label study
by: Wang Fujun, et al.
Published: (2007-08-01)

Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?
by: Rajarshi Guha Thakurta, et al.
Published: (2012-01-01)

Rapid response with ketamine on suicidal cognition in resistant depression
by: Rajarshi Guha Thakurta, et al.
Published: (2012-01-01)

The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study
by: Caroline J. K. Wallace, et al.
Published: (2021-02-01)

The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
by: Brittany O’Brien, et al.
Published: (2019-09-01)

Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression
by: Marcos Gómez-Revuelta, et al.
Published: (2020-12-01)

S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression
by: Fernanda S. Correia-Melo, et al.

Electrophysiological Correlates and Predictors of the Antidepressant Response to Repeated Ketamine Infusions in Treatment-Resistant Depression
by: de la Salle, Sara
Published: (2020)

Using Oral and Intranasal Dosage Forms of Ketamine for Managing Treatment-Resistant Depression: A Review of the Literature
by: Patrick Arthur Twohig, et al.
Published: (2016-07-01)

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
by: Hiroaki Hori, et al.
Published: (2012-01-01)

Fluvoxamine for the Treatment of Child and Adolescent Depression: An Open Label Trial
by: Ali Alavi, et al.
Published: (2008-12-01)

Fluvoxamine for the Treatment of Child and Adolescent Depression: An Open Label Trial
by: Ali Alavi, et al.
Published: (2008-12-01)

Low-dose ketamine infusion in treatment-resistant depression: a clinical, neurocognitive, inflammatory and neuroimaging study
by: Mu-Hong Chen, et al.
Published: (2018)

An open-label pilot study to explore usefulness of Homoeopathic treatment in nonerosive gastroesophageal reflux disease
by: Renu Mittal, et al.
Published: (2016-01-01)

Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study
by: Gregor Hasler, et al.
Published: (2020-07-01)

Adjunct ketamine treatment effects on treatment-resistant depressive symptoms in chronic treatment-resistant schizophrenia patients are short-term and disassociated from regional homogeneity changes in key brain regions – a pilot study
by: Jiaen Ye, et al.
Published: (2019-10-01)

Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression
by: Ginetta Collo, et al.
Published: (2018-01-01)

Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression
by: Ginetta Collo, et al.
Published: (2019-04-01)

Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression
by: Brittany O'Brien, et al.
Published: (2019-12-01)

Lithium and Valproate Levels Do Not Correlate with Ketamine’s Antidepressant Efficacy in Treatment-Resistant Bipolar Depression
by: Annie J. Xu, et al.
Published: (2015-01-01)